**ALLOCATION LIST (CONDENSED) OF AVAILABLE CLINICAL TRIALS AT ALTRU=7/17/2020**

**BREAST**

- ADJUVANT Node+, HER2-, any ERPR status allowed [A011502]
- RADIOTHERAPY IN BIOMARKER LOW RISK NODE + BREAST CA [MA.39]
- ADJUVANT Node+ or High-Risk Node- TNBC [NRG-BR003]
- TREATMENT AFTER NEOADJ CHEMO IN TNBC-RESIDUAL DISEASE [EA1131]

**CNS**

- NEWLY DIAGNOSED ANAPLASTIC GLIOMA [NCCTG N0577]

**LUNG**

- LIMITED STAGE SCLC [NRG-LU005]
- LS- OR EX-SCLC: MRI SURVEILLENCE w or w/o PCI [S1827]

**Cancer Control/Symptom Management**

- **ADJUVANT** Hypofractionated post-Mastectomy Rx with Breast Reconstruction [A221505]
- **PREVENTION** Olanzapine with or without Fosaprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC) [A221602]